Bharat Biotech rolls out first batch of Covaxin from Ankleshwar in Gujarat | Hyderabad News – Times of India

HYDERABAD: In a move that will augment the supply of indigenously developed Covid-19 vaccine Covaxin, Bharat Biotech has announced the rollout of the first commercial batch of Covaxin from its Chiron Behring Vaccines facility at Ankleshwar in Gujarat. Supplies of Covaxin doses from the Ankleshwar facility will start from September 2021.
The commercial Covaxin batches were launched by Union health minister Mansukh Mandaviya on Sunday at the facility in the presence of Bharat Biotech promoters Dr Krishna Ella and Suchitra Ella.
“A new filling facility, which was constructed during 2020 at Ankleshwar, is now being utilized for the production of Covaxin. Covaxin production had begun in early June, before which the team had executed engineering batches to study the equipment functionality at the facility,” Bharat Biotech said. The Ankleshwar facility was a BSL-2+ anti-rabies manufacturing facility that has been repurposed to produce 200 million doses of Covaxin per annum. Chiron Behring Vaccines is a wholly owned subsidiary of Bharat Biotech that was acquired in early 2019 from GlaxoSmithKline.
Bharat Biotech said it has already deployed multiple production lines at its Hyderabad, Malur-Bengaluru and Pune campuses, and the addition of the Ankleshwar plant will further augment its Covaxin capacities.
Commenting on the occasion, health minister Mansukh Mandaviya said: “India is focused on slowing the spread of Covid-19 in the country and the key to achieving this lies in the swift and efficient administration of vaccines. We want to ensure equitable access of the vaccine to every Indian citizen, and the expansion of Covaxin production facilities will take us closer to this goal.” “We want to ensure that Bharat Biotech can ably meet the demand for Covaxin such that individuals across the country, and the globe, have access to the vaccine. Our goal to develop a vaccine with global safety and efficacy standards has now been achieved. We are now marching towards the goal of annualised capacity of around 1 billion doses,” said Bharat Biotech chairman & managing director Dr Krishna Ella.
The company is also exploring manufacturing partnerships with its partners in other countries that have prior expertise with commercial scale manufacturing of inactivated viral vaccines under biosafety containment for further augmentation, it said.


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *